3,6-dimorpholino-9H-xanthen-9-one | 1079889-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,6-dimorpholino-9H-xanthen-9-one
• 英文别名: 3,6-di-morpholin-4-yl-xanthen-9-one；3,6-bis(N-morpholino)xanth-9-one；3,6-Dimorpholin-4-ylxanthen-9-one
• CAS: 1079889-18-1
• 化学式: C₂₁H₂₂N₂O₄
• 分子量: 366.417
• InChiKey: BEIPAMMCNWWVES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,6-dimorpholino-9H-xanthen-9-one 在 sodium methylate 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 54.0h， 生成
  参考文献：
  名称：

  Synthesis, evaluation, and biological applications of visible-light-controllable nitric oxide releasers

  摘要：

  DOI：

  10.1016/bs.mie.2020.04.002
• 作为产物：
  描述：

  吗啉 、 9-oxo-9H-xanthene-3,6-diyl bis(trifluoromethanesulfonate) 以 二甲基亚砜 为溶剂， 反应 12.0h， 以93%的产率得到3,6-dimorpholino-9H-xanthen-9-one
  参考文献：
  名称：

  具有环胺取代基的罗莎胺的合成和光谱性质。

  摘要：

  rosamines A和若丹明B之间存在紧密的结构相似性，但rosamine类中的各种结构及其光谱特性尚未深入研究。该手稿描述了一种简明的，可扩展的溶液相方法，可得到包括一些水溶性衍生物的罗莎明1-5和12-15。在一个测试案例（针对15个案例）中，还形成了一个示例性的蛋白质偶联物。在整个过程中，这些产物被分离和纯化，并且发现合成是可扩展的。此外，具有这些环胺取代基的罗莎胺显示出溶剂依赖性的荧光强度，并且在氯化烃中具有高的量子产率。在某些情况下，环胺取代基的性质显示出以pH依赖的方式调节母体分子的荧光。这些胺取代基的环大小也与其某些光谱性质相关。由一些加成产物1-5制备了几种水溶性的罗萨明，其中的15个之一通过酰胺键与抗生物素蛋白有效地缀合。15和15-亲和素在水性介质中的光谱性质非常相似。

  DOI：

  10.1021/jo800902j

文献信息

• [EN] ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE ROSAMINE COMME AGENTS POUR LE TRAITEMENT D'UN CANCER
  申请人：CANCER RES INITIATIVES FOUNDAT

  公开号：WO2010033011A1

  公开（公告）日：2010-03-25

  The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R1 represents aryl, Het1 or C1-6 alkyl, which latter group is optionally substituted by aryl or Het2; R2a and R2b together form C3.8n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4, alkyl.and which alkylene group is optionally interrupted by X1; R3a and R3b together form C3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4 alkyl, and which alkylene group is optionally interrupted by X2; X1 and X2 independently represent O, S, or NR4; R4 represents, independently at each occurrence, H, C(O)OR5, C(0)R6a, C(O)N(R6b)R6c or C1-6, alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het3 or is substituted by a single C(0)0R1a group; R4a represents H or C1-4 alkyl; R5 represents aryl, Het4 or C1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het5; R5e to R6d independently represent H or R5; each aryl independently represents a C6-10 carbocyclic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR7, phenyl, naphthyl and Het6) and OR8; R7 and R8 independently represent H, C1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR8a substituent), Het7, phenyl or naphthyl; R8a represents H or C1-4 alkyl; Het1 to Het7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or.more heteroatoms selected from oxygen, nitrogen and/or sulfur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR9 and phenyl) and OR10; R9 and R10 independently represent H, C1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A' represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using ' compounds as well as pharmaceutical compositions.

  本发明涉及一类新的罗萨明衍生物，其中在一个实施例中，化合物具有结构（I）或其任何药学上可接受的盐或溶剂，其中：R1代表芳基、Het1或C1-6烷基，后者可由芳基或Het2取代；R2a和R2b一起形成C3.8n-烷基，该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代，并且该烷基可由X1中断；R3a和R3b一起形成C3-6/7-烷基，该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代，并且该烷基可由X2中断；X1和X2独立地表示O、S或NR4；R4在每次出现时独立地表示H、C(O)OR5、C(0)R6a、C(O)N(R6b)R6c或C1-6烷基，后者可由卤素、芳基和Het3中选择的一个或多个取代基取代，或者由单个C(0)0R1a基团取代；R4a表示H或C1-4烷基；R5代表芳基、Het4或C1-6烷基，可由卤素、芳基和Het5中选择的一个或多个取代基取代；R5e到R6d独立地表示H或R5；每个芳基独立地表示一个含有6-10个碳环芳族的芳基，该芳基可能包含一个或两个环，并且可能被一个或多个取代基如卤素、CN、C1-6烷基（后者可由一个或多个取代基如卤素、OR7、苯基、萘基和Het6取代）和OR8取代；R7和R8独立地表示H、C1-4烷基（可由一个或多个卤素基或单个苯基或C(O)OR8a取代基取代）、Het7、苯基或萘基；R8a表示H或C1-4烷基；Het1到Het7独立地表示含有一个或多个异氧、氮和/或硫的芳族、完全饱和或部分不饱和的杂环基，这些杂环基可能包含一个或两个环，并且可能被一个或多个取代基如卤素、CN、C1-6烷基（后者可由一个或多个取代基如卤素、OR9和苯基取代）和OR10取代；R9和R10独立地表示H、C1-4烷基或苯基；除非另有规定，烷基可能由一个或多个卤素原子取代；A'表示药学上可接受的阴离子。还公开了制备和使用该化合物以及制药组合物的方法。
• ARYLETHYNYLXANTHENE DYES
  申请人：Ustinov Alexey

  公开号：US20120316319A1

  公开（公告）日：2012-12-13

  Disclosed are 9-arylethynylxanthenes which possess useful fluorescent properties, and can be used as fluorescent dyes, and labels.

  揭示了具有有用荧光性质的9-芳基乙炔基黄色素，可用作荧光染料和标记。
• ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER
  申请人：Lee Hong Boon

  公开号：US20110212955A1

  公开（公告）日：2011-09-01

  The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R 1 represents aryl, Het 1 or C 1-6 alkyl, which latter group is optionally substituted by aryl or Het 2 ; R 2a and R 2b together form C 3.8 n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C 1-4 alkyl, C(O)OH and C(O)O—C 1-4 , alkyl and which alkylene group is optionally interrupted by X 1 ; R 3a and R 3b together form C 3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo. C 1-4 alkyl, C(O)OH and C(O)O—C 1-4 alkyl, and which alkylene group is optionally interrupted by X 2 ; X 1 and X 2 independently represent O, S, or NR 4 ; R 4 represents, independently at each occurrence, H, C(O)OR 5 , C(O)R 6a , C(O)N(R 6b )R 6c or C 1-6 , alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het 3 or is substituted by a single C(O)OR 1a group; R 4a represents H or C 1-4 alkyl; R 5 represents aryl, Het 4 or C 1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het 5 ; R 5e to R 6d independently represent H or R 5 ; each aryl independently represents a C 6-10 carbocylic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C 1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR 7 , phenyl, napthyl and Het 6 ) and OR 8 ; R 7 and R 8 independently represent H, C 1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR 8a substituent), Het 7 , phenyl or naphthyl; R 8a represents H or C 1-4 alkyl; Het 1 to Het 7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulphur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C 1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR 9 and phenyl) and OR 10 ; R 9 and R 10 independently represent H, C 1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A′ represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions.

  本发明涉及一类新的罗萨明衍生物，其中在一种实施例中，化合物具有结构式（I）或其任何药学上可接受的盐或溶剂，其中：R1代表芳基，Het1或C1-6烷基，后一群基团可以被芳基或Het2取代；R2a和R2b共同形成C3.8n-烷基，该烷基可以被来自卤素，C1-4烷基，C（O）OH和C（O）O-C1-4烷基中的一个或多个取代基取代，并且该烷基可以被X1中断；R3a和R3b共同形成C3-6 / 7-烷基，该烷基可以被来自卤素，C1-4烷基，C（O）OH和C（O）O-C1-4烷基中的一个或多个取代基取代，并且该烷基可以被X2中断；X1和X2独立地表示O，S或NR4；R4在每次出现时独立地表示H，C（O）OR5，C（O）R6a，C（O）N（R6b）R6c或C1-6烷基，后一群基团可以被一个或多个来自卤素，芳基和Het3的取代基所取代，或被一个单独的C（O）OR1a基团所取代；R4a表示H或C1-4烷基；R5表示芳基，Het4或C1-6烷基，后一群基团可以被一个或多个来自卤素，芳基和Het5的取代基所取代；R5到R6d独立地表示H或R5；每个芳基独立地表示C6-10碳环芳基，该芳基可以包含一个或两个环，并且可以被一个或多个来自卤素，CN，C1-6烷基（后一群基团可以被一个或多个来自卤素，OR7，苯基，萘基和Het6的取代基所取代）和OR8的取代基所取代；R7和R8独立地表示H，C1-4烷基（可以被一个或多个卤素或单个苯基或C（O）OR8取代基所取代），Het7，苯基或萘基；R8a表示H或C1-4烷基；Het1到Het7独立地表示含有一个或多个来自氧，氮和/或硫的杂原子的5-至10元芳香，完全饱和或部分不饱和的杂环族群，该杂环族群可以包含一个或两个环，并且可以被一个或多个来自卤素，CN，C1-6烷基（后一群基团可以被一个或多个来自卤素，OR9和苯基的取代基所取代）和OR10的取代基所取代；R9和R10独立地表示H，C1-4烷基或苯基；除非另有说明，否则烷基可以被一个或多个卤素原子取代；A'表示药学上可接受的阴离子。还公开了制备和使用化合物以及制药组合物的方法。
• Antibacterial Potential of Symmetrical Twin-Drug 3,6-Diaminoxanthones
  作者：Diana I. S. P. Resende、Fernando Durães、Sidika Zubarioglu、Joana Freitas-Silva、Nikoletta Szemerédi、Madalena Pinto、Eugénia Pinto、Paulo Martins da Costa、Gabriella Spengler、Emília Sousa

  DOI：10.3390/ph17020209

  日期：——

  health worldwide. Antibiotic-resistant pathogenic bacteria, in particular, present a significant challenge. Therefore, there is an urgent need to identify new potential antimicrobial targets and discover new chemical entities that can potentially reverse bacterial resistance. The main goal of this research work was to create and develop a library of 3,6-disubstituted xanthones based on twin drugs and

  随着细菌、真菌、病毒和寄生虫引起的传染病的增加，全球健康面临着重大问题。越来越多的多重耐药微生物病原体严重威胁着全世界的公共卫生。尤其是对抗生素具有耐药性的病原菌，带来了重大挑战。因此，迫切需要确定新的潜在抗菌靶点并发现可以逆转细菌耐药性的新化学实体。这项研究工作的主要目标是基于双药和分子延伸方法创建和开发 3,6-二取代氧杂蒽酮库，以抑制外排泵的活性。该过程涉及通过 9-氧代-9H-呫吨-3,6-二基双（三氟甲磺酸）与各种伯胺和仲胺反应合成 3,6-二氨基呫吨酮。然后测试了所得的 3,6-二取代呫吨酮衍生物对一系列致病菌株的体外抗菌特性及其抑制外排泵活性、生物膜形成和群体感应的功效。几种化合物对测试的革兰氏阳性细菌表现出有效的抗菌特性。尤其是 Xanthone 16，对金黄色葡萄球菌 ATCC 25923 和粪肠球菌 ATCC 29212 参考菌株的 MIC 为 11 µM (4 µg/mL)，对耐甲氧西林金黄色葡萄球菌的
• Synthesis and Spectroscopic Properties of Rosamines with Cyclic Amine Substituents
  作者：Liangxing Wu、Kevin Burgess

  DOI：10.1021/jo800902j

  日期：2008.11.21

  rosamines with these cyclic amine substituents display solvent-dependent fluorescence intensities, and high quantum yields in chlorinated hydrocarbons. In some cases the nature of the cyclic amine substituent was shown to modulate the fluorescence of the parent molecules in pH-dependent ways. The ring size of those amine substituents also correlated with some of their spectroscopic properties. Several water-soluble

  rosamines A和若丹明B之间存在紧密的结构相似性，但rosamine类中的各种结构及其光谱特性尚未深入研究。该手稿描述了一种简明的，可扩展的溶液相方法，可得到包括一些水溶性衍生物的罗莎明1-5和12-15。在一个测试案例（针对15个案例）中，还形成了一个示例性的蛋白质偶联物。在整个过程中，这些产物被分离和纯化，并且发现合成是可扩展的。此外，具有这些环胺取代基的罗莎胺显示出溶剂依赖性的荧光强度，并且在氯化烃中具有高的量子产率。在某些情况下，环胺取代基的性质显示出以pH依赖的方式调节母体分子的荧光。这些胺取代基的环大小也与其某些光谱性质相关。由一些加成产物1-5制备了几种水溶性的罗萨明，其中的15个之一通过酰胺键与抗生物素蛋白有效地缀合。15和15-亲和素在水性介质中的光谱性质非常相似。